Horizon Therapeutics (HZNP) – Hot FDA News
-
Horizon Therapeutics (HZNP) Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population
-
Horizon Therapeutics (HZNP) Announces Phase 2 Study of Dazodalibep (HZN-4920) Meets Primary Endpoint in Rheumatoid Arthritis
-
-
-
-
-
-
-
-
-
Back to HZNP Stock Lookup